TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1429086

Group type: EXPERIMENTAL
Intervention: 20 Gy (10 x 2 Gy) to the hemithorax + CYVADIC (cyclophosphamide 500 mg/m2 d 1, vincristine 1 mg/m2 d 1 and 5, adriamycin 40 mg/m2 d 1 and dacarbazine 200 mg/m2 d 1 and 5, several cycles before and after irradiation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 55 Gy (25 x 2.2 Gy) to the hemithorax + 15 Gy (6 x 2.5 Gy) to the tumor + CYVADIC (2 cycles before, 1 cycle during, and 2 cycles after irradiation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg/m2 q 28 d, < or = 6 cycles) followed by 70 Gy (56 x 1.25 Gy, twice a day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 4‐Epirubicin (110‐130 mg/m2 q 28 d, < or = 6 cycles) followed by 35 Gy (28 x 1.25 Gy twice a day) to the hemithorax + 36 Gy (9 x 4 Gy every 2 days) to the tumor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etoposide (150 mg/m2 1, 3, 5 q 28 d) followed by 38.5 Gy (11 x 3.5 Gy) to the hemithorax
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment programs
Number of subjects: 100
Study: 3882141

Group type: EXPERIMENTAL
Intervention: Cyclosporine (12.5 mg/kg/d orally or 3 mg/kg/d i.v.)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 112
Study: 31204776

Group type: EXPERIMENTAL
Intervention: CBT-based occupational therapy with sensor monitoring
Number of subjects: 240

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 240
Study: 30325357

Group type: EXPERIMENTAL
Intervention: Chronic noise exposure
Number of subjects: 250

Group type: COMPARATOR
Intervention: Protective equipment to control noise
Number of subjects: 250
Study: 25932956

Group type: EXPERIMENTAL
Intervention: Galactose (GAL) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucose (GLU) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA) drink (artificially sweetened, 45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Galactose (GAL) drink (45 g of CHO)
Number of subjects: 9
Study: 25284708

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity group (n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Structured exercise group (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care control group (n=30)
Number of subjects: 90
Study: 22500388

Group type: EXPERIMENTAL
Intervention: QYBCR (qi supplementing, yin nourishing, blood stasis dispersing, collateral dredging recipe)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: QYBCR
Number of subjects: 78

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 78
Study: 19804966

Group type: EXPERIMENTAL
Intervention: PSA screening in Rotterdam (intervention group)
Number of subjects: 149257

Group type: COMPARATOR
Intervention: No PSA screening in Northern Ireland (control group)
Number of subjects: 149257
Study: 17643057

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 x 600 mg orally for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 30
Study: 16226162

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 4162
Study: 12394531

Group type: EXPERIMENTAL
Intervention: Piracetam (7.2 g daily for the first 2 weeks during ECT, followed by 4.8 g thereafter)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (identical-looking)
Number of subjects: 38
Study: 10687162

Group type: EXPERIMENTAL
Intervention: Diosmectite (3 g/day for children under 3 years and 6 g/day for children over 3 years)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) only
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diosmectite and ORS
Number of subjects: 35
Study: 8656345

Group type: EXPERIMENTAL
Intervention: Empirical and model‐based methods for estimating AUC and Cmax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model‐based sampling times obtained by software
Number of subjects: 0
Study: 2205129

Group type: EXPERIMENTAL
Intervention: Fasting for 2 hours with 2 mL/kg of water
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fasting for 4 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fasting for 6 hours
Number of subjects: 100
Study: 720003

Group type: EXPERIMENTAL
Intervention: Propranolol (single dose)
Number of subjects: 0
Study: 30223083

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 28838475

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 62
Study: 25377657

Group type: EXPERIMENTAL
Intervention: Daily low-emission UV treatment and mometasone ointment 0.1%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mometasone ointment 0.1% alone
Number of subjects: 62
Study: 22704916

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 777

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 777
Study: 21317700

Group type: EXPERIMENTAL
Intervention: Assessment and documentation practices of emergency department nurses for MTBI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alignment with CDC guidelines for MTBI assessment
Number of subjects: 0
Study: 19594043

Group type: EXPERIMENTAL
Intervention: EKRL training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined group (EKRL training + Meloxicam)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (Meloxicam only)
Number of subjects: 150
Study: 17266171

Group type: EXPERIMENTAL
Intervention: 12‐h tobacco‐deprived smokers
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nondeprived smokers
Number of subjects: 90
Study: 15016023

Group type: EXPERIMENTAL
Intervention: Hand instrumentation (curettes, hoes and files)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reciprocating power-driven instruments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined use of ultrasonic scaler and power-driven inserts
Number of subjects: 20
Study: 12049082

Group type: EXPERIMENTAL
Intervention: Conventional glass‐ionomer cement (Ketac‐Molar aplicap)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Composite resin (Heliomolar)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin modified glass‐ionomer (Fuji II LC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Compomer restorative material (Compoglass)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Compomer restorative material (Hytac)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Compomer restorative material (Dyract)
Number of subjects: 60
Study: 9786104

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 48
Study: 7838889

Group type: EXPERIMENTAL
Intervention: 100 mg BMS-181168
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg BMS-181168
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mg BMS-181168
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3283620

Group type: EXPERIMENTAL
Intervention: Intensive maintenance treatment (rotating combination of HD‐Ara C, mAMSA, 5‐AZA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Repeated induction type chemotherapy (DNM, VCR, Ara C)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional maintenance treatment (from a preceding randomized study)
Number of subjects: 63
Study: 29413364

Group type: EXPERIMENTAL
Intervention: 1.5g/day Arachidonic acid (ARA) for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 19
Study: 28662808

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Metallic drug-eluting stent (DES)
Number of subjects: 359
Study: 25650633

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular blockade with 30 mL of 0.5% ropivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ultrasound-guided infraclavicular blockade with 30 mL of 0.5% ropivacaine
Number of subjects: 64
Study: 23974885

Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCLs) for 3 months, replaced every 30 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ocular lubricants (OLs) 4 times a day with Lacri-Lube ointment at night for 3 months
Number of subjects: 29
Study: 19788708

Group type: COMPARATOR
Intervention: Conventional dietetic advice for CHD
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Behavioural counselling for Mediterranean diet
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nutritional counselling for Mediterranean diet
Number of subjects: 61
Study: 18775918

Group type: EXPERIMENTAL
Intervention: Adjunctive manual thrombectomy
Number of subjects: 2417

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2417
Study: 16416358

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Amitriptyline-gabapentin combination
Number of subjects: 56
Study: 12888055

Group type: EXPERIMENTAL
Intervention: Eger Macular Stressometer (EMS) for AMD group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Eger Macular Stressometer (EMS) for normal/mild cataract group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Eger Macular Stressometer (EMS) for diabetic retinopathy group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Eger Macular Stressometer (EMS) for glaucoma group
Number of subjects: 92
Study: 10700783

Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.5 mg kg‐1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg kg‐1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Org 9488 (main metabolite)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 42

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 42
Study: 8947715

Group type: EXPERIMENTAL
Intervention: Biweekly electronic mail message with computer-generated report summarizing adherence to care guidelines for diabetic patients.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no individualized feedback).
Number of subjects: 45
Study: 2016605

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty (Charnley)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Noncemented total hip arthroplasty (HP‐Garches)
Number of subjects: 150
Study: 6105476

Group type: EXPERIMENTAL
Intervention: Intra-operative B-mode ultrasound scanning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Per-operative cholangiography
Number of subjects: 50
Study: 31905382

Group type: EXPERIMENTAL
Intervention: Biosimilar adalimumab (SB5)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Originator adalimumab
Number of subjects: 93
Study: 31481365

Group type: EXPERIMENTAL
Intervention: Tibial tuberoplasty
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 140
Study: 28054939

Group type: EXPERIMENTAL
Intervention: trans-resveratrol
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 25786811

Group type: EXPERIMENTAL
Intervention: 50 ml ropivacaine 0.5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 125 ml ropivacaine 0.2%
Number of subjects: 90

Group type: COMPARATOR
Intervention: 50 ml 0.9% saline (placebo)
Number of subjects: 90
Study: 23208003

Group type: EXPERIMENTAL
Intervention: TVT-S
Number of subjects: 122

Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 122
Study: 21131387

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 30
Study: 19546825

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10, 20, or 40 mg
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 1583
Study: 16678642

Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg QD
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg QD
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg QD
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg BID
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1093
Study: 15706857

Group type: EXPERIMENTAL
Intervention: AS and PNS
Number of subjects: 94

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 94
Study: 11426121

Group type: EXPERIMENTAL
Intervention: Clinicians assessing samples containing various concentrations of blood diluted in urine for gross hematuria.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinicians' interpretations of gross hematuria.
Number of subjects: 0
Study: 9250559

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg administered orally once/day for 12 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administered once/day for 12 days
Number of subjects: 16
Study: 8318063

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg once daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study: 3554990

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 29720027

Group type: EXPERIMENTAL
Intervention: Testosterone enantholactam acid ester (250 mg, intramuscular injection every 2 weeks for 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (intramuscular injection every 2 weeks for 6 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testosterone enantholactam acid ester
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25779603

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline HAQ DI score
Number of subjects: 0
Study: 24909248

Group type: EXPERIMENTAL
Intervention: Psychodynamic group psychotherapy (PGP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 22393376

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20127900

Group type: EXPERIMENTAL
Intervention: Saline infusion
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Saline infusion plus N-acetylcysteine (NAC)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) infusion
Number of subjects: 156
Study: 17078067

Group type: EXPERIMENTAL
Intervention: Bilateral Vim DBS activated
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bilateral Vim DBS deactivated
Number of subjects: 21
Study: 15232793

Group type: EXPERIMENTAL
Intervention: Ca-bread (2.5% elemental calcium by weight)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Calcium acetate (control group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ca-bread
Number of subjects: 53
Study: 11716652

Group type: EXPERIMENTAL
Intervention: Multicomponent workplace health promotion program provided over 4 days and a follow-up program over 1 year
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Multicomponent workplace health promotion program
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study: 9111486

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (42 micrograms)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7510737

Group type: EXPERIMENTAL
Intervention: 220 mmol/day NaCl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3117914

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) pre-operatively
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Codeine phosphate (30 mg) pre-operatively
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen/codeine (400 mg/30 mg) pre-operatively
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Placebo pre-operatively
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen/codeine (400 mg/30 mg) post-operatively
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Diflunisal (250 mg) post-operatively
Number of subjects: 155
Study: 29540293

Group type: EXPERIMENTAL
Intervention: G8 screening tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VES-13 screening tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mFP screening tool
Number of subjects: 0
Study: 27300113

Group type: EXPERIMENTAL
Intervention: Stretching (10 minutes daily before bedtime for 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 40
Study: 25491726

Group type: EXPERIMENTAL
Intervention: Community hospital admission (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General hospital admission (group 2)
Number of subjects: 60
Study: 22800656

Group type: EXPERIMENTAL
Intervention: Flanker task with high calorie distractors
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Flanker task while hungry
Number of subjects: 139
Study: 20155309

Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training (RIT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 18545070

Group type: EXPERIMENTAL
Intervention: High-dose simvastatin (80 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-dose simvastatin (20 mg/day)
Number of subjects: 31
Study: 15714981

Group type: EXPERIMENTAL
Intervention: Mitoxantrone combined with prednisone (or hydrocortisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estramustine and taxane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 0
Study: 15324531

Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times daily
Number of subjects: 96
Study: 11760378

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy at a dose of 20 ppm
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no iNO therapy)
Number of subjects: 47
Study: 9406362

Group type: EXPERIMENTAL
Intervention: Teicoplanin administered at the time of insertion of central venous catheters
Number of subjects: 65

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 65
Study: 8123209

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 and 60 mg, PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine, Verapamil, Alcohol (in combination)
Number of subjects: 0
Study: 2886515

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (hypoglycemia prevented)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 7
Study: 30452459

Group type: EXPERIMENTAL
Intervention: Highly alkaline water (EG; n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular table water (CG; n = 8)
Number of subjects: 16
Study: 28876476

Group type: EXPERIMENTAL
Intervention: School Breakfast Program participation (SBP)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Food establishment use
Number of subjects: 404
Study: 24403295

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 38
Study: 23806212

Group type: EXPERIMENTAL
Intervention: Trichodermin
Number of subjects: 0
Study: 21199047

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group training (Social Competence Training for Adolescents with Borderline Intelligence)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 18084781

Group type: EXPERIMENTAL
Intervention: Behavioral-medical rehabilitation approach
Number of subjects: 361

Group type: COMPARATOR
Intervention: Traditional rehabilitation approach
Number of subjects: 361
Study: 16517365

Group type: EXPERIMENTAL
Intervention: Camera covers with adhesive tape sealing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All tested camera covers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Type of cover with the largest diameter and arthroscope adapter
Number of subjects: 90
Study: 14520164

Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ), 5 to 10 mg for 30 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ) for 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: P3 latency
Number of subjects: 23

Group type: COMPARATOR
Intervention: CRTV
Number of subjects: 23
Study: 11881701

Group type: EXPERIMENTAL
Intervention: Lying for 5 minutes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lying for 10 minutes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Standing for 0 minutes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Standing for 2 minutes
Number of subjects: 35
Study: 9412304

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg twice daily, for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 19
Study: 1396648

Group type: EXPERIMENTAL
Intervention: Endurance exercise at 85% of Th(an,ind) (EEE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Endurance exercise at 95% of Th(an,ind) (IEE)
Number of subjects: 34
Study: 4069863

Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 14